Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Production chapter

Butane is primarily used as a fuel gas within the LPG mixture. Like ethane and propane, the main chemical use of butane is as feedstock for steam cracking units for olefin production. Dehydrogenation of n-butane to butenes and to butadiene is an important route for the production of synthetic rubber. n-Butane is also a starting material for acetic acid and maleic anhydride production (Chapter 6). [Pg.32]

Normal paraffins in this range are important intermediates for alkylating benzene for synthetic detergents production (Chapter 10). They are also good feedstocks for single-cell protein (SCP). [Pg.53]

In the petrochemical field, hydrogen is used to hydrogenate benzene to cyclohexane and benzoic acid to cyclohexane carboxylic acid. These compounds are precursors for nylon production (Chapter 10). It is also used to selectively hydrogenate acetylene from C4 olefin mixture. [Pg.113]

Urea possesses a unique property of forming adducts with n-paraffms. This is used in separating C12-C14 n-paraffms from kerosines for detergent production (Chapter 6). [Pg.147]

In Europe naphtha is the preferred feedstock for the production of synthesis gas, which is used to synthesize methanol and ammonia (Chapter 4). Another important role for naphtha is its use as a feedstock for steam cracking units for light olefins production (Chapter 3). Heavy naphtha, on the other hand, is a major feedstock for catalytic reforming. The product reformate containing a high percentage of Ce-Cg aromatic hydrocarbons is used to make gasoline. Reformates are also extracted to separate the aromatics as intermediates for petrochemicals. [Pg.182]

Table 1-2 provides estimates of the major types of plastics consumed yearly worldwide that now total 339,990 million lb (154 million tons). About 90% are thermoplastics (TPs) and 10% thermoset (TS) plastics. USA and Europe consumption s are each about one-third of the world total. There are well over 35,000 different type plastic materials worldwide. However, most of them are not used in large quantities they have specific performance and/or cost capabilities generally for specific products by specific processes that principally include many thousands of products (Chapters 6 7). [Pg.10]

The mechanical behavior of plastics is dominated by such viscoelastic phenomena as tensile strength, elongation at breaks, stiffness, and rupture energy, which are often the controlling factors in a design. The viscous attributes of plastic melt flow are also important considerations in the fabrication of plastic products. (Chapter 8, INFLUENCE ON PERFORMANCE, Viscoelasticity). [Pg.39]

There are several ways in which the impact properties of plastics can be improved if the material selected does not have sufficient impact strength. One method is by altering the composition of the material so that it is no longer a glassy plastic at the operating temperature of the product (Chapter 6). In the case of PVC this is done by the addition of an impact modifier which can be a compatible plastic such as an acrylic or a nitrile rubber. The addition of such a material lowers the glass transition temperature and the material becomes a rubbery viscoelastic plastic with much improved impact properties. This is one of the methods in which PVC materials are made to exhibit superior impact properties. [Pg.92]

Conventional machining operations are used preferably from the same plastic to be used in the product (Chapter 8, SECONDARY EQUIPMENT). Different casting techniques are used that provide low cost even though they are usually labor intensive. The casting of unfilled or filled/reinforced plastic used include TS polyurethane, epoxy, structural foam, and RTV silicone. Also used are die cast metals. [Pg.178]

The fatigue strength is defined as that stress level at which the test specimen will sustain N cycles prior to failure. The data are generated on a machine that runs at 1800 cycles per minute. This test is of value to material manufacturers in determining consistency of their product (Chapter 2). [Pg.316]

Surprisingly, very little physiological work has been done to understand the nature and processes of plant recovery from extreme drought stress, especially in relation to plant production (Chapter 7). In order for the plant to recover properly from severe water stress, its various meristems must survive. The association between severe plant stress and the factors that affect meristem survival and function upon rehydration are unclear though osmoregulation may have a possible protective role and as a potential source of carbon for recovery. Active plant apices generally excel in osmoregulation and do not lose much water upon plant dehydration (Barlow, Munns Brady, 1980). [Pg.207]

No medical or therapeutic procedure comes without some risk to the patient. All possible steps are taken to ensure safely, quahty and efficacy of vaccines and immunological products (Chapter 15). The risks associated with immunization procedures must be constantly reviewed and balanced against the risks of, and associated with, contracting the disease, hi this respect, smallpox vaccination in the UK was abandoned in the mid 1970s as the risks associated with vaccination then exceeded the predicted number of deaths that would follow importation of the disease. Shortly after this, in 1980, The World Health Assembly pronounced the world to be free of smallpox. Similarly, the incidence of paralytic poliomyelitis in the USA and UK in 1996 was low but the majority of cases related to vaccine use. As the worldwide elimination of poliomyelitis approaches, there is much debate as to the value of the vaccine outside of an endemic area. [Pg.326]

Part II provides detailed information on the main quality and safety issues related to the production of organic livestock foods. This includes three chapters (Chapters 7 to 9) which review the effect of livestock husbandry on nutritional and sensory quality of livestock foods including milk and dairy products (Chapter 7), poultry (Chapter 8) and pork (Chapter 9). It also includes four chapters (Chapters 10 to 13) which review the strategies used to minimise microbiological risks and antibiotic and veterinary medicine use in livestock production systems including safety of ruminants (Chapter 10), mastitis treatment in organic dairy production systems (Chapter 11), internal parasites (Chapter 12) and pigs and poultry (Chapter 13). [Pg.3]

It overcomes the problem of source availability. Many proteins of therapeutic potential are produced naturally in the body in minute quantities. Examples include interferons (Chapter 8), interleukins (Chapter 9) and colony-stimulating factors (CSFs Chapter 10). This rendered impractical their direct extraction from native source material in quantities sufficient to meet likely clinical demand. Recombinant production (Chapters 3 and 5) allows the manufacture of any protein in whatever quantity it is required. [Pg.5]

In addition to the studies listed in Figure 4.5, stability characteristics of the protein with regard to e.g. temperature, pH and incubation with various potential excipients are studied. Such information is required in order to identify a suitable final product formulation, and to give an early indication of the likely useful shelf-life of the product (Chapter 6). [Pg.67]

Pulmonary delivery currently represents the most promising alternative to parenteral delivery systems for biopharmaceuticals. Delivery via the pulmonary route moved from concept to reality in 2006 with the approval of Exubera, an inhalable insulin product (Chapter 11). Although the lung is not particularly permeable to solutes of low molecular mass (e.g. sucrose or urea), macromolecules can be absorbed into the blood via the lungs surprisingly well. In fact, pulmonary... [Pg.71]

The expression of recombinant proteins in cells in which they do not naturally occur is termed heterologous protein production (Chapter 3). The first biopharmaceutical produced by genetic engineering to gain marketing approval (in 1982) was recombinant human insulin (tradename Humulin ), produced in E. coli. An example of a more recently approved biopharmaceutical that is produced in E. coli is that of Kepivance, a recombinant keratinocyte growth factor used to treat oral mucositis (Chapter 10). Many additional examples are provided in subsequent chapters. [Pg.106]

Up until this point, it was assumed that naked DNA injected into animals would not be spontaneously taken up and expressed in host cells. This finding vindicated the cautious approach taken by the FDA and other regulatory authorities with regard to the presence of free DNA in biophar-maceutical products (Chapter 7). [Pg.432]

Coke does not offer the same potential environmental issues as other petroleum products (Chapter 10 and above). It is used predominantly as a refinery fuel unless other uses for the production of a high-grade coke or carbon are desired. In the former case, the constituents of the coke that will release environmentally harmful gases such as nitrogen oxides, sulfur oxides, and particulate matter should be known. In addition, stockpiling coke on a site where it awaits use or transportation can lead to leachates as a result of rainfall (or acid rainfall) which are highly detrimental. In such a case, application of the toxicity characteristic leaching procedure... [Pg.294]

The chapter dealing with examples of retrosynthetic analysis and the corresponding total synthesis has been enlarged and includes new syntheses of natural products (Chapter 13). [Pg.550]

Crowther, J. B., Salomons, P. and Callaghan, C., Analytical Method Development for Assay and Impurity Determination in Drug Substances and Drug Products, Chapter 12. In Analytical Chemistry in a GMP Environment, Miller, J. M. and Crowther, J. B., Eds., John Wiley Sons, Inc., New York, 2000. [Pg.189]

Figure 8.16 The control of amino acid breakdown and protein synthesis in liver. The factors in regulation are as follows (i) the amino acid concentration in the blood regulates the rate of urea production (Chapter 10) (ii) the amino acid leucine, and the anabolic hormones increase the rate of protein synthesis. Mass action is a term used to describe the effect of concentration of substrate on the reaction rate. The control of protein synthesis is discussed in Chapter 20. Control by leucine has been studied primarily in muscle. Figure 8.16 The control of amino acid breakdown and protein synthesis in liver. The factors in regulation are as follows (i) the amino acid concentration in the blood regulates the rate of urea production (Chapter 10) (ii) the amino acid leucine, and the anabolic hormones increase the rate of protein synthesis. Mass action is a term used to describe the effect of concentration of substrate on the reaction rate. The control of protein synthesis is discussed in Chapter 20. Control by leucine has been studied primarily in muscle.
The second part deals with applications of solvent extraction in industry, and begins with a general chapter (Chapter 7) that involves both equipment, flowsheet development, economic factors, and environmental aspects. Chapter 8 is concerned with fundamental engineering concepts for multistage extraction. Chapter 9 describes contactor design. It is followed by the industrial extraction of organic and biochemical compounds for purification and pharmaceutical uses (Chapter 10), recovery of metals for industrial production (Chapter 11), applications in the nuclear fuel cycle (Chapter 12), and recycling or waste treatment (Chapter 14). Analytical applications are briefly summarized in Chapter 13. The last chapters, Chapters 15 and 16, describe some newer developments in which the principle of solvent extraction has or may come into use, and theoretical developments. [Pg.31]


See other pages where Production chapter is mentioned: [Pg.9]    [Pg.5]    [Pg.178]    [Pg.229]    [Pg.457]    [Pg.8]    [Pg.344]    [Pg.587]    [Pg.25]    [Pg.403]    [Pg.489]    [Pg.2]    [Pg.4]    [Pg.4]    [Pg.779]    [Pg.940]    [Pg.217]    [Pg.159]    [Pg.519]    [Pg.540]    [Pg.394]    [Pg.489]    [Pg.207]    [Pg.382]    [Pg.418]    [Pg.50]   
See also in sourсe #XX -- [ Pg.11 , Pg.322 ]




SEARCH



Bibliography for Chapter Q. Synthetic Pharmaceutical Products

Full-scale test production (chapter

Hydrogen production, Chapter

Hydrogen production, Chapter costs

Phase 1 Products Conceptualization (chapter

Product design 1 (chapter

Product formulation (chapter

Product manufacture (chapter

Product quality (chapter

Production carrier (chapter

© 2024 chempedia.info